Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?

Tempus AI (TEM) reported robust Q1 2025 revenue growth of 75% year-over-year, driven by an 89% jump in genomics, and secured a $200 million deal with AstraZeneca and Pathos for an oncology foundation model. Its shares have surged 91.8% year-to-date, significantly outperforming NVIDIA's (NVDA) 29.2% gain, and it trades at a more attractive forward price-to-sales ratio of 7.84 compared to NVIDIA's 18.96. While NVIDIA remains a critical enabler of AI infrastructure in healthcare, Tempus AI's faster growth, strategic partnerships, and more favorable valuation position it as a potentially stronger short-term opportunity in the AI-health tech sector, despite both holding a Zacks Rank #3 (Hold).

Analysis

Tempus AI (TEM) is demonstrating significant momentum in the AI-driven healthcare market, distinguishing itself from the sector's infrastructure leader, NVIDIA (NVDA). Tempus reported a 75% year-over-year revenue increase in its first quarter, propelled by an 89% surge in its core genomics business. This top-line acceleration is reflected in its stock performance, which has surged 91.8% year-to-date, substantially outpacing NVIDIA's 29.2% gain. A key strategic development for Tempus is its pivot towards becoming a leading AI platform in oncology, underscored by a $200 million, three-year partnership with AstraZeneca and Pathos to develop a large-scale foundation model, which leverages its extensive 300-petabyte clinical data asset. In contrast, while NVIDIA is integral to the ecosystem through its partnerships and platforms like BioNeMo, its valuation appears stretched at a forward price-to-sales (P/S) ratio of 18.96, above its one-year median. Tempus AI trades at a more attractive 7.84 forward P/S, below its median, suggesting a more favorable risk/reward profile despite both companies carrying a Zacks Rank #3 (Hold) and having similar short-term analyst price target upsides of approximately 5%.

Key Decisions for Investors

• Investors seeking direct exposure to AI applications in precision medicine may find Tempus AI's focused model, superior 75% revenue growth, and more attractive valuation compelling compared to NVIDIA's broader, infrastructure-oriented role.
• The execution of Tempus AI's $200 million partnership with AstraZeneca and Pathos is a critical catalyst to monitor, as its success will validate the strategic shift toward a high-margin data and AI platform business.
• Given that both companies hold a Zacks Rank #3 (Hold) and analyst targets suggest modest near-term upside of around 5%, maintaining current positions or considering selective accumulation may be more prudent than initiating aggressive new long positions in either stock.